These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 30502333

  • 1. Changes in physicochemical properties of kidney cells membrane as a consequence of hypertension and treatment of hypertensive rats with FAAH inhibitor.
    Dobrzyńska I, Szachowicz-Petelska B, Weresa J, Figaszewski ZA, Skrzydlewska E.
    Chem Biol Interact; 2019 Feb 01; 299():52-58. PubMed ID: 30502333
    [Abstract] [Full Text] [Related]

  • 2. Effects of hypertension and FAAH inhibitor treatment of rats with primary and secondary hypertension considering the physicochemical properties of erythrocytes.
    Dobrzyńska I, Szachowicz-Petelska B, Pędzińska-Betiuk A, Figaszewski ZA, Skrzydlewska E.
    Toxicol Mech Methods; 2020 May 01; 30(4):297-305. PubMed ID: 32028814
    [Abstract] [Full Text] [Related]

  • 3. Age-specific influences of chronic administration of the fatty acid amide hydrolase inhibitor URB597 on cardiovascular parameters and organ hypertrophy in DOCA-salt hypertensive rats.
    Toczek M, Baranowska-Kuczko M, Grzęda E, Pędzińska-Betiuk A, Weresa J, Malinowska B.
    Pharmacol Rep; 2016 Apr 01; 68(2):363-9. PubMed ID: 26922540
    [Abstract] [Full Text] [Related]

  • 4. Redox system and phospholipid metabolism in the kidney of hypertensive rats after FAAH inhibitor URB597 administration.
    Biernacki M, Ambrożewicz E, Gęgotek A, Toczek M, Bielawska K, Skrzydlewska E.
    Redox Biol; 2018 May 01; 15():41-50. PubMed ID: 29197803
    [Abstract] [Full Text] [Related]

  • 5. Long-term administration of fatty acid amide hydrolase inhibitor (URB597) to rats with spontaneous hypertension disturbs liver redox balance and phospholipid metabolism.
    Biernacki M, Ambrożewicz E, Gęgotek A, Toczek M, Skrzydlewska E.
    Adv Med Sci; 2019 Mar 01; 64(1):15-23. PubMed ID: 30243113
    [Abstract] [Full Text] [Related]

  • 6. Protective role of cannabinoid CB1 receptors and vascular effects of chronic administration of FAAH inhibitor URB597 in DOCA-salt hypertensive rats.
    Baranowska-Kuczko M, Kozłowska H, Kloza M, Karpińska O, Toczek M, Harasim E, Kasacka I, Malinowska B.
    Life Sci; 2016 Apr 15; 151():288-299. PubMed ID: 26969765
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Crosstalk between liver antioxidant and the endocannabinoid systems after chronic administration of the FAAH inhibitor, URB597, to hypertensive rats.
    Biernacki M, Łuczaj W, Gęgotek A, Toczek M, Bielawska K, Skrzydlewska E.
    Toxicol Appl Pharmacol; 2016 Jun 15; 301():31-41. PubMed ID: 27086176
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hypertension and chronic inhibition of endocannabinoid degradation modify the endocannabinoid system and redox balance in rat heart and plasma.
    Biernacki M, Malinowska B, Timoszuk M, Toczek M, Jastrząb A, Remiszewski P, Skrzydlewska E.
    Prostaglandins Other Lipid Mediat; 2018 Sep 15; 138():54-63. PubMed ID: 30201316
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The influence of DOCA-salt hypertension and chronic administration of the FAAH inhibitor URB597 on KCa2.3/KCa3.1-EDH-type relaxation in rat small mesenteric arteries.
    Kloza M, Baranowska-Kuczko M, Malinowska B, Karpińska O, Harasim-Symbor E, Kasacka I, Kozłowska H.
    Vascul Pharmacol; 2017 Dec 15; 99():65-73. PubMed ID: 29038048
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. URB597 reduces biochemical, behavioral and morphological alterations in two neurotoxic models in rats.
    Maya-López M, Ruiz-Contreras HA, de Jesús Negrete-Ruíz M, Martínez-Sánchez JE, Benítez-Valenzuela J, Colín-González AL, Villeda-Hernández J, Sánchez-Chapul L, Parra-Cid C, Rangel-López E, Santamaría A.
    Biomed Pharmacother; 2017 Apr 15; 88():745-753. PubMed ID: 28157650
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.